Imprimis Pharmaceuticals Stock Price, News & Analysis (NASDAQ:IMMY)

$1.62 -0.04 (-2.41 %)
(As of 01/19/2018 04:00 PM ET)
Previous Close$1.62
Today's Range$1.60 - $1.66
52-Week Range$1.35 - $4.69
Volume56,695 shs
Average Volume146,747 shs
Market Capitalization$34.09 million
P/E Ratio-1.76
Dividend YieldN/A
Beta-0.51

About Imprimis Pharmaceuticals (NASDAQ:IMMY)

Imprimis Pharmaceuticals logoImprimis Pharmaceuticals, Inc. (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. The Company, through its Imprimis Cares program, owns, markets and dispenses a portfolio of compounded therapeutic in several therapeutic areas, including ophthalmology, urology, otolaryngology and infectious diseases. The Company is also developing Custom Compounding Choice business, which is focused on developing and dispensing a portfolio of non-proprietary compounded drugs for humans and animals in therapeutic areas that may be overlooked by commercial pharmaceutical companies. The Company also offers customizable compounding products that consist of sterile injectable and non-sterile integrative medicine therapies that are used in various therapeutic areas.

Receive IMMY News and Ratings via Email

Sign-up to receive the latest news and ratings for IMMY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:IMMY
CUSIPN/A
Phone858-704-4040

Debt

Debt-to-Equity Ratio3.94%
Current Ratio1.67%
Quick Ratio1.28%

Price-To-Earnings

Trailing P/E Ratio-1.76086956521739
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$19.94 million
Price / Sales1.67
Cash FlowN/A
Price / CashN/A
Book Value$0.35 per share
Price / Book4.63

Profitability

Trailing EPS($0.92)
Net Income$-19,080,000.00
Net Margins-60.71%
Return on Equity-264.98%
Return on Assets-57.30%

Miscellaneous

Employees144
Outstanding Shares20,540,000

Imprimis Pharmaceuticals (NASDAQ:IMMY) Frequently Asked Questions

What is Imprimis Pharmaceuticals' stock symbol?

Imprimis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IMMY."

How were Imprimis Pharmaceuticals' earnings last quarter?

Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) released its earnings results on Tuesday, November, 14th. The specialty pharmaceutical company reported ($0.28) EPS for the quarter. Imprimis Pharmaceuticals had a negative return on equity of 264.98% and a negative net margin of 60.71%. View Imprimis Pharmaceuticals' Earnings History.

When will Imprimis Pharmaceuticals make its next earnings announcement?

Imprimis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March, 19th 2018. View Earnings Estimates for Imprimis Pharmaceuticals.

Where is Imprimis Pharmaceuticals' stock going? Where will Imprimis Pharmaceuticals' stock price be in 2018?

1 Wall Street analysts have issued twelve-month price targets for Imprimis Pharmaceuticals' stock. Their predictions range from $5.00 to $5.00. On average, they anticipate Imprimis Pharmaceuticals' stock price to reach $5.00 in the next twelve months. View Analyst Ratings for Imprimis Pharmaceuticals.

Who are some of Imprimis Pharmaceuticals' key competitors?

Who are Imprimis Pharmaceuticals' key executives?

Imprimis Pharmaceuticals' management team includes the folowing people:

  • Robert J. Kammer D.D.S, Chairman of the Board (Age 64)
  • Mark L. Baum J.D., Chief Executive Officer, Director (Age 44)
  • Andrew R. Boll CFA, Chief Financial Officer, Secretary (Age 32)
  • John P. Saharek, Chief Commercial Officer (Age 55)
  • Stephen G. Austin CPA, Independent Director (Age 62)
  • Richard L. Lindstrom M.D., Independent Director (Age 69)
  • Anthony J. Principi J.D., Independent Director (Age 72)

How do I buy Imprimis Pharmaceuticals stock?

Shares of Imprimis Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Imprimis Pharmaceuticals' stock price today?

One share of Imprimis Pharmaceuticals stock can currently be purchased for approximately $1.62.

How big of a company is Imprimis Pharmaceuticals?

Imprimis Pharmaceuticals has a market capitalization of $34.09 million and generates $19.94 million in revenue each year. The specialty pharmaceutical company earns $-19,080,000.00 in net income (profit) each year or ($0.92) on an earnings per share basis. Imprimis Pharmaceuticals employs 144 workers across the globe.

How can I contact Imprimis Pharmaceuticals?

Imprimis Pharmaceuticals' mailing address is 12264 El Camino Real Suite 350, San Diego CA, 92130. The specialty pharmaceutical company can be reached via phone at 858-704-4040 or via email at [email protected]


MarketBeat Community Rating for Imprimis Pharmaceuticals (IMMY)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  82 (Vote Outperform)
Underperform Votes:  82 (Vote Underperform)
Total Votes:  164
MarketBeat's community ratings are surveys of what our community members think about Imprimis Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Imprimis Pharmaceuticals (NASDAQ:IMMY) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $5.00$5.00$5.00$5.00
Price Target Upside: 101.61% upside101.61% upside101.61% upside101.61% upside

Imprimis Pharmaceuticals (NASDAQ:IMMY) Consensus Price Target History

Price Target History for Imprimis Pharmaceuticals (NASDAQ:IMMY)

Imprimis Pharmaceuticals (NASDAQ:IMMY) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/22/2017Rodman & RenshawReiterated RatingBuy$5.00HighView Rating Details
11/28/2016HC WainwrightInitiated CoverageBuy$5.00N/AView Rating Details
(Data available from 1/20/2016 forward)

Earnings

Imprimis Pharmaceuticals (NASDAQ:IMMY) Earnings History and Estimates Chart

Earnings by Quarter for Imprimis Pharmaceuticals (NASDAQ:IMMY)

Imprimis Pharmaceuticals (NASDAQ IMMY) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/19/2018N/AView Earnings Details
11/14/2017Q3 2017($0.28)ViewN/AView Earnings Details
8/10/2017Q2 2017($0.23)$0.06$6.86 millionViewN/AView Earnings Details
5/10/2017Q1 2017($0.19)($0.26)$6.50 million$6.10 millionViewN/AView Earnings Details
3/21/2017Q4 2016($0.28)($0.44)$5.50 million$5.79 millionViewN/AView Earnings Details
11/14/2016Q316($0.24)($0.29)$2.70 million$4.90 millionViewN/AView Earnings Details
8/15/2016Q216($0.35)$4.53 million$4.90 millionViewListenView Earnings Details
5/12/2016Q116($0.27)($0.43)$3.24 million$4.40 millionViewListenView Earnings Details
3/23/2016Q415($0.26)($0.53)$3.52 million$3.50 millionViewListenView Earnings Details
11/12/2015Q3 2015($0.43)($0.41)ViewN/AView Earnings Details
8/12/2015Q215($0.33)($0.39)$2.13 million$2.00 millionViewListenView Earnings Details
5/13/2015Q115($0.25)($0.33)$1.55 million$16.00 millionViewN/AView Earnings Details
3/12/2015Q414($0.25)($0.30)$0.68 million$0.55 millionViewN/AView Earnings Details
11/12/2014Q3 2014($0.27)ViewN/AView Earnings Details
8/13/2014Q2 2014($0.28)ViewN/AView Earnings Details
5/15/2014Q1 2014($0.26)ViewN/AView Earnings Details
3/28/2014Q4 2013($0.21)ViewN/AView Earnings Details
11/6/2013Q3 2013($0.23)ViewN/AView Earnings Details
8/14/2013Q2 2013($0.25)ViewN/AView Earnings Details
5/8/2013Q1 2013($0.19)ViewN/AView Earnings Details
11/8/2010Q3 2010($1.20)($1.88)ViewN/AView Earnings Details
8/12/2010Q2 2010($1.20)($1.20)ViewN/AView Earnings Details
5/13/2010Q1 2010($2.40)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Imprimis Pharmaceuticals (NASDAQ:IMMY) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Imprimis Pharmaceuticals (NASDAQ:IMMY)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Imprimis Pharmaceuticals (NASDAQ IMMY) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 12.55%
Institutional Ownership Percentage: 12.64%
Insider Trades by Quarter for Imprimis Pharmaceuticals (NASDAQ:IMMY)
Insider Trades by Quarter for Imprimis Pharmaceuticals (NASDAQ:IMMY)

Imprimis Pharmaceuticals (NASDAQ IMMY) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/17/2017Robert J KammerDirectorSell10,000$3.05$30,500.001,059,827View SEC Filing  
12/19/2016Andrew R BollCFOBuy39,000$1.79$69,810.0054,000View SEC Filing  
12/19/2016Mark L BaumCEOBuy156,000$1.79$279,240.00325,835View SEC Filing  
12/19/2016Richard L Md LindstromDirectorBuy100,000$1.79$179,000.00100,000View SEC Filing  
3/11/2016Opaleye Management Inc.Major ShareholderBuy45,000$3.65$164,250.00View SEC Filing  
6/30/2015Opaleye Management Inc.Major ShareholderBuy35,000$7.90$276,500.00View SEC Filing  
5/19/2015Donald Paul MiloniMajor ShareholderSell410,000$8.00$3,280,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Imprimis Pharmaceuticals (NASDAQ IMMY) News Headlines

Source:
DateHeadline
NasdaqCM Healthcare Industry: A Deep Dive Into Imprimis Pharmaceuticals Inc (NASDAQ:IMMY)NasdaqCM Healthcare Industry: A Deep Dive Into Imprimis Pharmaceuticals Inc (NASDAQ:IMMY)
finance.yahoo.com - January 15 at 11:04 AM
Head to Head Comparison: Imprimis Pharmaceuticals (IMMY) versus The CompetitionHead to Head Comparison: Imprimis Pharmaceuticals (IMMY) versus The Competition
www.americanbankingnews.com - January 11 at 11:16 PM
Head-To-Head Analysis: Imprimis Pharmaceuticals (IMMY) and Its PeersHead-To-Head Analysis: Imprimis Pharmaceuticals (IMMY) and Its Peers
www.americanbankingnews.com - January 11 at 3:34 PM
Reviewing Imprimis Pharmaceuticals (IMMY) and Its RivalsReviewing Imprimis Pharmaceuticals (IMMY) and Its Rivals
www.americanbankingnews.com - January 6 at 11:52 AM
Is Imprimis Pharmaceuticals Inc’s (NASDAQ:IMMY) CEO Pay Justified?Is Imprimis Pharmaceuticals Inc’s (NASDAQ:IMMY) CEO Pay Justified?
finance.yahoo.com - January 4 at 3:43 PM
ETFs with exposure to Imprimis Pharmaceuticals, Inc. : December 26, 2017ETFs with exposure to Imprimis Pharmaceuticals, Inc. : December 26, 2017
finance.yahoo.com - December 26 at 12:21 PM
Imprimis Pharmaceuticals, Inc. :IMMY-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017Imprimis Pharmaceuticals, Inc. :IMMY-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017
finance.yahoo.com - December 25 at 4:24 PM
Head to Head Review: Imprimis Pharmaceuticals (IMMY) versus Its CompetitorsHead to Head Review: Imprimis Pharmaceuticals (IMMY) versus Its Competitors
www.americanbankingnews.com - December 23 at 7:24 PM
Critical Survey: Imprimis Pharmaceuticals (IMMY) vs. Its RivalsCritical Survey: Imprimis Pharmaceuticals (IMMY) vs. Its Rivals
www.americanbankingnews.com - December 16 at 11:28 AM
Imprimis Pharmaceuticals Inc (IMMY): Has Recent Earnings Growth Beaten Long-Term Trend?Imprimis Pharmaceuticals Inc (IMMY): Has Recent Earnings Growth Beaten Long-Term Trend?
finance.yahoo.com - November 29 at 3:43 PM
Imprimis Pharmaceuticals Announces Third Quarter 2017 ResultsImprimis Pharmaceuticals Announces Third Quarter 2017 Results
finance.yahoo.com - November 15 at 2:55 AM
Investor Network Invites You to the Imprimis Pharmaceuticals Third Quarter 2017 Earnings Conference Call and Webcast Live on Tuesday, November 14, 2017Investor Network Invites You to the Imprimis Pharmaceuticals Third Quarter 2017 Earnings Conference Call and Webcast Live on Tuesday, November 14, 2017
finance.yahoo.com - November 13 at 7:54 PM
Short Interest in Imprimis Pharmaceuticals, Inc. (IMMY) Grows By 70.6%Short Interest in Imprimis Pharmaceuticals, Inc. (IMMY) Grows By 70.6%
www.americanbankingnews.com - November 13 at 3:34 AM
ETFs with exposure to Imprimis Pharmaceuticals, Inc. : November 10, 2017ETFs with exposure to Imprimis Pharmaceuticals, Inc. : November 10, 2017
finance.yahoo.com - November 11 at 12:11 PM
Imprimis Pharmaceuticals, Inc. (IMMY) Set to Announce Earnings on MondayImprimis Pharmaceuticals, Inc. (IMMY) Set to Announce Earnings on Monday
www.americanbankingnews.com - November 6 at 5:44 AM
Imprimis Pharmaceuticals to Host its Third Quarter 2017 Financial Report Conference Call and Webcast on November 14, 2017 at 4:15 p.m. ESTImprimis Pharmaceuticals to Host its Third Quarter 2017 Financial Report Conference Call and Webcast on November 14, 2017 at 4:15 p.m. EST
finance.yahoo.com - October 31 at 10:23 PM
Imprimis Launches Surface Pharmaceuticals SubsidiaryImprimis Launches Surface Pharmaceuticals Subsidiary
finance.yahoo.com - October 25 at 6:27 AM
What does Imprimis Pharmaceuticals Inc’s (IMMY) Balance Sheet Tell Us Abouts Its Future?What does Imprimis Pharmaceuticals Inc’s (IMMY) Balance Sheet Tell Us Abouts Its Future?
finance.yahoo.com - October 21 at 2:16 AM
Imprimis To Challenge Allergans Restasis With Cheaper ProductImprimis To Challenge Allergan's Restasis With Cheaper Product
seekingalpha.com - October 20 at 5:17 AM
Imprimis Pharmaceuticals (IMMY) Has Spiked To Nearly A 2-Month HighImprimis Pharmaceuticals (IMMY) Has Spiked To Nearly A 2-Month High
www.rttnews.com - October 20 at 5:17 AM
Imprimis Pharmaceuticals to Offer Compounded Cyclosporine Alternative to Restasis®Imprimis Pharmaceuticals to Offer Compounded Cyclosporine Alternative to Restasis®
finance.yahoo.com - October 20 at 12:13 AM
Imprimis Pharmaceuticals Inc (IMMY) Stock: Gaining On Generic Version of RestasisImprimis Pharmaceuticals Inc (IMMY) Stock: Gaining On Generic Version of Restasis
finance.yahoo.com - October 20 at 12:13 AM
Imprimis Pharma to take on Allergans Restasis with cheaper productImprimis Pharma to take on Allergan's Restasis with cheaper product
finance.yahoo.com - October 20 at 12:13 AM
ETFs with exposure to Imprimis Pharmaceuticals, Inc. : October 17, 2017ETFs with exposure to Imprimis Pharmaceuticals, Inc. : October 17, 2017
finance.yahoo.com - October 18 at 1:17 AM
ETFs with exposure to Imprimis Pharmaceuticals, Inc. : October 6, 2017ETFs with exposure to Imprimis Pharmaceuticals, Inc. : October 6, 2017
finance.yahoo.com - October 6 at 11:11 PM
What’s The Outlook For Loss-Making Imprimis Pharmaceuticals Inc (IMMY)?What’s The Outlook For Loss-Making Imprimis Pharmaceuticals Inc (IMMY)?
finance.yahoo.com - October 5 at 9:50 PM
Imprimis Pharmaceuticals Secures First Key Composition Patent for Dropless Therapy® FormulationsImprimis Pharmaceuticals Secures First Key Composition Patent for Dropless Therapy® Formulations
finance.yahoo.com - October 2 at 1:08 PM
Critical Contrast: Prothena Corporation PLC (PRTA) & Imprimis Pharmaceuticals (IMMY)Critical Contrast: Prothena Corporation PLC (PRTA) & Imprimis Pharmaceuticals (IMMY)
www.americanbankingnews.com - September 25 at 8:54 AM
ETFs with exposure to Imprimis Pharmaceuticals, Inc. : September 22, 2017ETFs with exposure to Imprimis Pharmaceuticals, Inc. : September 22, 2017
finance.yahoo.com - September 22 at 1:57 PM
Imprimis Pharmaceuticals, Inc. :IMMY-US: Earnings Analysis: Q2, 2017 By the Numbers : September 20, 2017Imprimis Pharmaceuticals, Inc. :IMMY-US: Earnings Analysis: Q2, 2017 By the Numbers : September 20, 2017
finance.yahoo.com - September 20 at 4:15 PM
Allergan: Is Imprimis Spat Another Ruse To Crush Restasis Competitor?Allergan: Is Imprimis Spat Another Ruse To Crush Restasis Competitor?
seekingalpha.com - September 20 at 5:58 AM
FDA Curcumin Investigation Supports Imprimis StatementFDA Curcumin Investigation Supports Imprimis Statement
finance.yahoo.com - September 15 at 12:55 AM
Imprimis Pharmaceuticals (IMMY) and MyoKardia (MYOK) Financial SurveyImprimis Pharmaceuticals (IMMY) and MyoKardia (MYOK) Financial Survey
www.americanbankingnews.com - September 12 at 11:00 AM
Imprimis Releases Statement Regarding Allergan LawsuitImprimis Releases Statement Regarding Allergan Lawsuit
finance.yahoo.com - September 11 at 8:36 PM
Imprimis Pharmaceuticals, Inc. (IMMY) Announces Quarterly  Earnings ResultsImprimis Pharmaceuticals, Inc. (IMMY) Announces Quarterly Earnings Results
www.americanbankingnews.com - August 11 at 7:54 PM
Imprimis Pharmaceuticals Announces Second Quarter 2017 Financial ResultsImprimis Pharmaceuticals Announces Second Quarter 2017 Financial Results
www.bizjournals.com - August 11 at 3:53 AM
Investor Network Invites You to the Imprimis Pharmaceuticals Second Quarter 2017 Earnings Conference Call and Webcast Live on Thursday, August 10, 2017Investor Network Invites You to the Imprimis Pharmaceuticals Second Quarter 2017 Earnings Conference Call and Webcast Live on Thursday, August 10, 2017
finance.yahoo.com - August 9 at 8:08 PM
Imprimis Pharma (IMMY) Issues Statement on Curcumin Emulsion FDA MedWatch NoticeImprimis Pharma (IMMY) Issues Statement on Curcumin Emulsion FDA MedWatch Notice
www.streetinsider.com - August 8 at 12:23 AM
Imprimis Statement Regarding Curcumin Emulsion FDA MedWatch NoticeImprimis Statement Regarding Curcumin Emulsion FDA MedWatch Notice
finance.yahoo.com - August 7 at 7:21 PM
FDA Links Naturopathic Turmeric Death To Contaminated ProductFDA Links Naturopathic Turmeric Death To Contaminated Product
finance.yahoo.com - August 5 at 6:40 PM
Imprimis Pharmaceuticals to Host its Second Quarter 2017 Financial Report Conference Call and Webcast on August 10, 2017 at 4:15 p.m. EDTImprimis Pharmaceuticals to Host its Second Quarter 2017 Financial Report Conference Call and Webcast on August 10, 2017 at 4:15 p.m. EDT
finance.yahoo.com - July 31 at 7:14 PM
Imprimis Pharmaceuticals Patent-Pending Dropless and LessDrops Formulations Exceed One Million Patient Eyes MilestoneImprimis Pharmaceuticals Patent-Pending Dropless and LessDrops Formulations Exceed One Million Patient Eyes Milestone
finance.yahoo.com - July 27 at 10:32 PM
Imprimis Pharmaceuticals Announces $16 Million Debt Facility with SWK HoldingsImprimis Pharmaceuticals Announces $16 Million Debt Facility with SWK Holdings
finance.yahoo.com - July 20 at 11:37 PM
Imprimis Pharmaceuticals, Inc. (IMMY) Director Sells $30,500.00 in StockImprimis Pharmaceuticals, Inc. (IMMY) Director Sells $30,500.00 in Stock
www.americanbankingnews.com - July 19 at 8:22 PM
Imprimis Spins Off Eton Pharmaceuticals To Challenge Pricey Pipelines Of Mallinckrodt, EndoImprimis Spins Off Eton Pharmaceuticals To Challenge Pricey Pipelines Of Mallinckrodt, Endo
www.benzinga.com - June 20 at 11:52 PM
Imprimis Pharma (IMMY) Buys Exclusive License to Patented Ophthalmic Formulation for Dry Eye DiseaseImprimis Pharma (IMMY) Buys Exclusive License to Patented Ophthalmic Formulation for Dry Eye Disease
www.streetinsider.com - April 7 at 10:25 AM
Imprimis Pharmaceuticals (IMMY) CEO Mark Baum on Q4 2016 Results - Earnings Call TranscriptImprimis Pharmaceuticals' (IMMY) CEO Mark Baum on Q4 2016 Results - Earnings Call Transcript
seekingalpha.com - March 22 at 6:04 PM
8:01 am Imprimis Pharmaceuticals entered into agreements with two accredited investors for a registered direct placement of 1,312,000 shares of common stock at a price of $2.40 per share8:01 am Imprimis Pharmaceuticals entered into agreements with two accredited investors for a registered direct placement of 1,312,000 shares of common stock at a price of $2.40 per share
us.rd.yahoo.com - March 22 at 9:56 AM
IMPRIMIS PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, FinanciaIMPRIMIS PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financia
biz.yahoo.com - March 22 at 9:56 AM
Imprimis Pharmaceuticals Announces Fourth Quarter and Year-End 2016 Financial ResultsImprimis Pharmaceuticals Announces Fourth Quarter and Year-End 2016 Financial Results
us.rd.yahoo.com - March 21 at 5:53 PM

SEC Filings

Imprimis Pharmaceuticals (NASDAQ:IMMY) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Imprimis Pharmaceuticals (NASDAQ:IMMY) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Imprimis Pharmaceuticals (NASDAQ IMMY) Stock Chart for Saturday, January, 20, 2018

Loading chart…

This page was last updated on 1/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.